Cara Therapeutics, Inc. (NASDAQ:CARA) insider Scott Terrillion sold 1,946 shares of Cara Therapeutics stock in a transaction dated Wednesday, December 30th. The shares were sold at an average price of $15.30, for a total value of $29,773.80. Following the transaction, the insider now owns 42,436 shares of the company’s stock, valued at approximately $649,270.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ CARA opened at $15.13 on Friday. Cara Therapeutics, Inc. has a 52-week low of $8.88 and a 52-week high of $19.13. The business’s 50 day moving average is $15.21 and its two-hundred day moving average is $15.45.
Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Saturday, November 14th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.25. The company had revenue of $9.27 million for the quarter, compared to analyst estimates of $4.98 million. Cara Therapeutics had a negative return on equity of 64.36% and a negative net margin of 360.35%. Analysts predict that Cara Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.
CARA has been the topic of several analyst reports. BidaskClub lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 18th. Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 22nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price target on shares of Cara Therapeutics in a research report on Tuesday, September 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Cara Therapeutics presently has an average rating of “Buy” and a consensus target price of $30.80.
Several large investors have recently bought and sold shares of CARA. Swiss National Bank grew its stake in shares of Cara Therapeutics by 21.5% in the second quarter. Swiss National Bank now owns 99,000 shares of the biopharmaceutical company’s stock worth $1,693,000 after acquiring an additional 17,500 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Cara Therapeutics in the second quarter worth $367,000. State of Wisconsin Investment Board grew its stake in shares of Cara Therapeutics by 7.3% in the second quarter. State of Wisconsin Investment Board now owns 66,000 shares of the biopharmaceutical company’s stock worth $1,129,000 after acquiring an additional 4,500 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Cara Therapeutics by 2.8% in the second quarter. Bank of New York Mellon Corp now owns 183,748 shares of the biopharmaceutical company’s stock worth $3,142,000 after acquiring an additional 4,963 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Cara Therapeutics by 52.3% in the second quarter. Goldman Sachs Group Inc. now owns 323,159 shares of the biopharmaceutical company’s stock worth $5,526,000 after acquiring an additional 110,935 shares in the last quarter. Institutional investors and hedge funds own 64.43% of the company’s stock.
About Cara Therapeutics
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Article: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.